Using ultrasound microvessel imaging to evaluate ovarian and adnexal lesions
Ultrasound Imaging of Ovarian and Adnexal Lesions
NA · Mayo Clinic · NCT07280312
This test tries to see if ultrasound microvessel imaging can better detect small blood vessels in adults scheduled for surgery for ovarian or adnexal lesions.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Mayo Clinic (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Rochester, Minnesota) |
| Trial ID | NCT07280312 on ClinicalTrials.gov |
What this trial studies
This interventional imaging study adds ultrasound microvessel imaging (UMI) to standard transvaginal ultrasound for adults who are already scheduled for surgical removal of an ovarian or adnexal lesion. Participants will undergo UMI before their planned surgery, and the imaging findings will be compared with the surgical and pathological results to determine how well UMI identifies microvascular patterns associated with malignancy. The study excludes pregnant patients, those who have already had the lesion removed, and patients receiving neoadjuvant systemic therapy. All imaging and care are performed at Mayo Clinic in Rochester, Minnesota.
Who should consider this trial
Good fit: Adult women (age 18 or older) who are scheduled for surgical treatment of an ovarian or adnexal lesion and who are not pregnant, have not previously had the lesion removed, and are not receiving neoadjuvant chemotherapy are ideal candidates.
Not a fit: People who are not planning surgery, who are pregnant, who already had their lesion removed, or who are receiving neoadjuvant systemic therapy are unlikely to benefit from this imaging study.
Why it matters
Potential benefit: If successful, UMI could help distinguish benign from malignant adnexal lesions before surgery and improve preoperative planning.
How similar studies have performed: UMI is a newer ultrasound technique with some preliminary work showing improved detection of small vessels in other settings, but its accuracy for ovarian and adnexal lesions is still largely unproven and being actively studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female patients aged ≥ 18 years * Scheduled for surgery for ovarian or adnexal lesions Exclusion Criteria: * Prior surgical removal of ovarian or adnexal lesions * Undergoing neoadjuvant chemotherapy or targeted systemic therapy * Vulnerable populations, including prisoners, adults lacking capacity to consent, and pregnant women (our study coordinator will ask participants if they are pregnant; if uncertain, a urine pregnancy test will be offered at no cost).
Where this trial is running
Rochester, Minnesota
- Mayo Clinic in Rochester — Rochester, Minnesota, United States (RECRUITING)
Study contacts
- Principal investigator: Shigao D. Chen, PhD — Mayo Clinic
- Study coordinator: Clinical Trials Referral Office
- Email: mayocliniccancerstudies@mayo.edu
- Phone: 855-776-0015
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Female Reproductive System Adnexal Neoplasm, Ovarian Carcinoma, Female Reproductive System Neoplasm, Ovarian Neoplasms, Adnexal Lesion, Ovarian Lesion